Camrelizumab (AiRuiKa)
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, camrelizumab binds to and blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens.
Toxicity management
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Classical Hodgkin lymphoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer, squamous
- Non-small cell lung cancer, nonsquamous
History of changes in NMPA indication
- 2019-05-29: Initial approval
- 2021-06-17: Approved combined with gemcitabine and cisplatin (GP) as a first-line treatment for the patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). (Based on CAPTAIN-1st)
Also known as
- Code names: HR-301210, SHR-1210
- Generic name: carrelizumab
- Brand names: AiRuiKa, Erica
- Drugs
- Intravenous medications
- Anti-PD-1 antibodies
- Esophageal squamous cell carcinoma medications
- Hepatocellular carcinoma medications
- Classical Hodgkin lymphoma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- NMPA approved in 2019